Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,060 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00179881 | Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma | completed | Phase 2 | 47 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 |
| clinicaltrials |
| NCT03291314 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma(GliAvAx) | completed | Phase 2 | 52 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | completed | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01767415 | Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection | completed | Phase 1 / Phase 2 | 10 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00038441 | Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038493 | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00323115 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00400816 | Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma | completed | Phase 2 | 29 | The Cleveland ClinicOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | completed | Phase 2 | 58 | Massachusetts General HospitalOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT00782626 | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | completed | Phase 2 | 23 | Huashan HospitalOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02478164 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01450826 | Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | completed | Phase 2 | 136 | Katy PetersOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT02157103 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | completed | Phase 2 | 3 | Emory UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT01602588 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)(HCQ) | completed | Phase 2 | 54 | University College, LondonOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT00003456 | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | completed | Phase 2 | 127 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00047320 | Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors | completed | Phase 2 | 104 | Children's Oncology GroupNETWORK | 5 | Feb 14, 2018 | clinicaltrials |
| NCT00068250 | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 60 | Radiation Therapy Oncology GroupNETWORK | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00766753 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 22 | Frank LiebermanOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00782756 | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | completed | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | completed | Phase 2 | 135 | Hoffmann-La RocheINDUSTRY | 8 | Feb 5, 2018 | clinicaltrials |
| NCT00619112 | Temozolomide in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02971319 | Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma | completed | Phase 2 | 32 | Proactina S.A.OTHER | 2 | Jan 26, 2018 | clinicaltrials |
| NCT00003473 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas | completed | Phase 2 | 20 | Burzynski Research InstituteOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme(ACT III) | completed | Phase 2 | 82 | Celldex TherapeuticsINDUSTRY | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00387790 | Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03388372 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | completed | Phase 2 | 39 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | completed | Phase 2 | 1 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT02707549 | Fluid Therapy During Brain Tumor Resection in Children | completed | Phase 2 | 53 | Federal University of São PauloOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00859040 | Monthly SOM230C for Recurrent or Progressive Meningioma | completed | Phase 2 | 34 | Patrick Y. Wen, MDOTHER | 1 | Oct 27, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2019source: clinicaltrials